Urist Marshall 4

What Happened

• Urist Marshall, Executive Vice President, Research & Investments at Royalty Pharma (RPRX), sold 9,098 Class A ordinary shares in open‑market transactions on June 24, 2026.
• The reported weighted average sale price was $55.18 per share, for total proceeds of approximately $502,067.

Key Details

• Transaction date: 2026-06-24 (reported on Form 4 filed 2026-06-25); transaction code: S (sale).
• Price: weighted average $55.18; sales occurred across prices ranging from $54.77 to $55.31 per share (footnote indicates the seller can provide a per‑trade breakdown on request).
• Plan: All reported sales were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on February 12, 2026 (pre‑planned sale).
• Shares owned after transaction: the Form 4 does not list direct post‑sale shareholdings; the filing’s remarks state the reporting person and family vehicles hold limited partnership interests exchangeable into 2,474,120 Class A shares and Class E ordinary shares exchangeable into 1,356,528 Class A shares of RPH (Class E shares are subject to vesting conditions).
• Timeliness: Filed the day after the trade (within the Form 4 reporting window), so not indicated as late.

Context

• This was a sale executed under a pre-arranged 10b5-1 plan, which is commonly used to schedule insider trades and does not by itself indicate the insider’s current view of the company.
• No options were exercised and no gifts or tax withholdings are reported in this transaction.